全文获取类型
收费全文 | 94075篇 |
免费 | 29052篇 |
国内免费 | 1067篇 |
专业分类
耳鼻咽喉 | 2392篇 |
儿科学 | 2491篇 |
妇产科学 | 2242篇 |
基础医学 | 2008篇 |
口腔科学 | 4995篇 |
临床医学 | 25499篇 |
内科学 | 23774篇 |
皮肤病学 | 3219篇 |
神经病学 | 11817篇 |
特种医学 | 3513篇 |
外科学 | 17499篇 |
综合类 | 105篇 |
现状与发展 | 40篇 |
一般理论 | 1篇 |
预防医学 | 13028篇 |
眼科学 | 2059篇 |
药学 | 841篇 |
中国医学 | 7篇 |
肿瘤学 | 8664篇 |
出版年
2024年 | 740篇 |
2023年 | 5009篇 |
2022年 | 1073篇 |
2021年 | 2644篇 |
2020年 | 5276篇 |
2019年 | 1927篇 |
2018年 | 6774篇 |
2017年 | 7259篇 |
2016年 | 7819篇 |
2015年 | 7916篇 |
2014年 | 10277篇 |
2013年 | 11922篇 |
2012年 | 3445篇 |
2011年 | 3192篇 |
2010年 | 6641篇 |
2009年 | 8943篇 |
2008年 | 3199篇 |
2007年 | 2130篇 |
2006年 | 3329篇 |
2005年 | 1865篇 |
2004年 | 1270篇 |
2003年 | 981篇 |
2002年 | 899篇 |
2001年 | 1780篇 |
2000年 | 1108篇 |
1999年 | 1646篇 |
1998年 | 2042篇 |
1997年 | 1872篇 |
1996年 | 1928篇 |
1995年 | 1666篇 |
1994年 | 1064篇 |
1993年 | 897篇 |
1992年 | 727篇 |
1991年 | 618篇 |
1990年 | 496篇 |
1989年 | 505篇 |
1988年 | 489篇 |
1987年 | 368篇 |
1986年 | 342篇 |
1985年 | 284篇 |
1984年 | 244篇 |
1983年 | 292篇 |
1982年 | 219篇 |
1981年 | 192篇 |
1980年 | 118篇 |
1978年 | 119篇 |
1977年 | 114篇 |
1976年 | 83篇 |
1974年 | 70篇 |
1972年 | 70篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
4.
5.
6.
7.
Harvey A. Siegal PhD ; Paul J. Draus PhD ; Robert G. Carlson PhD ; Russel S. Falck MA ; Jichuan Wang PhD 《The Journal of rural health》2006,22(2):169-173
CONTEXT: Although the nonmedical use of stimulant drugs such as cocaine and methamphetamine is increasingly common in many rural areas of the United States, little is known about the health beliefs of people who use these drugs. PURPOSE: This research describes illicit stimulant drug users' views on health and health-related concepts that may affect their utilization of health care services. METHODS: A respondent-driven sampling plan was used to recruit 249 not-in-treatment, nonmedical stimulant drug users who were residing in 3 rural counties in west central Ohio. A structured questionnaire administered by trained interviewers was used to collect information on a range of topics, including current drug use, self-reported health status, perceived need for substance abuse treatment, and beliefs about health and health services. FINDINGS: Participants reported using a wide variety of drugs nonmedically, some by injection. Alcohol and marijuana were the most commonly used drugs in the 30 days prior to the interview. Powder cocaine was used by 72.3% of the sample, crack by 68.3%, and methamphetamine by 29.7%. Fair or poor health status was reported by 41.3% of the participants. Only 20.9% of the sample felt they needed drug abuse treatment. Less than one third of the sample reported that they would feel comfortable talking to a physician about their drug use, and 65.1% said they preferred taking care of their problems without getting professional help. CONCLUSIONS: Stimulant drug users in rural Ohio are involved with a range of substances and hold health beliefs that may impede health services utilization. 相似文献
8.
Clinical decisions are often made with incomplete information, yet patient care decisions are made every day. Patients vary clinically, uncertainty exists in diagnostic and prognostic information, and many preventive and treatment alternatives have not been formally assessed for their effectiveness. Because scientific information will never answer all clinical questions, clinical decisions are partially based on probabilistic information.
This paper describes how to apply clinical decision making to diagnosing and managing dental caries and periodontal diseases. By using explicit information to quantify probabilities and outcomes, clinical decision making analyzes decisions made under uncertain conditions and the uncertain impact of clinical information.
Clinical decision making incorporates concepts for preventing, diagnosing and treating dental caries and periodontal diseases: risk assessment, evidence-based dentistry, and multiple oral health outcomes. This information can serve as a tool for clinicians to augment clinical judgment and expertise. 相似文献
This paper describes how to apply clinical decision making to diagnosing and managing dental caries and periodontal diseases. By using explicit information to quantify probabilities and outcomes, clinical decision making analyzes decisions made under uncertain conditions and the uncertain impact of clinical information.
Clinical decision making incorporates concepts for preventing, diagnosing and treating dental caries and periodontal diseases: risk assessment, evidence-based dentistry, and multiple oral health outcomes. This information can serve as a tool for clinicians to augment clinical judgment and expertise. 相似文献
9.
Allison J. Cowin PhD ; Nicholas Hatzirodos BSc ; Justin Rigden PhD ; Robert Fitridge FRACS ; David A. Belford PhD 《Wound repair and regeneration》2006,14(4):421-426
High levels of tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine, are present in the wound fluid of chronic nonhealing wounds. This leads to increased inflammation, cytokine expression, and ultimately results in impaired wound healing and tissue destruction. Etanercept is a recombinant fusion protein that consists of the soluble TNF receptor (p75) linked to the Fc portion of human IgG1. It is an effective inhibitor of TNF-alpha and has been shown to provide rapid and sustained improvement in rheumatoid arthritis by acting as a soluble receptor binding TNF-alpha and preventing its proinflammatory activities. Therefore, the aim of this study was to determine whether Etanercept could inhibit TNF-alpha activity in chronic wound fluid. Wound fluid was collected from the venous leg ulcers of 16 different patients. The effect of Etanercept on TNF-alpha activity was evaluated using both a TNF-alpha bioassay and an enzyme-linked immunoassay. Etanercept was found to reduce the cytotoxic effect of chronic wound fluid on L929 fibroblasts by approximately 30% and neutralized TNF-alpha binding in the enzyme-linked immunoassay by up to 80%. Direct application of Etanercept to chronic wounds may therefore reduce the inflammatory activity of TNF-alpha, which could reduce the chronicity of venous leg ulcers and thus aid in the healing of these wounds. 相似文献
10.